Magali Grange

发表

Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B

J. Ghysdael, J. Nunès, R. Roncagalli, 2015, Immunology.

IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas

L. Leserman, P. Naquet, L. Chasson, 2015, Oncoimmunology.

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

L. Leserman, A. Schmitt‐Verhulst, M. Buferne, 2012, Cancer research.

Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-bet–Dependent Tc1 Program with Repressed IL-6/TGF-β1 Signaling

S. Spicuglia, Julien Maurizio, A. Griffon, 2013, The Journal of Immunology.

Signaling 1 β Program with Repressed IL-6 / TGF-Dependent Tc 1 − and Imprints a T-bet Eomesodermin Expression in CD 8 T Cells Active STAT 5 Regulates T-bet and

S. Spicuglia, Julien Maurizio, A. Griffon, 2013 .

Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

M. Buferne, N. Auphan-Anezin, G. Verdeil, 2013, Pigment cell & melanoma research.

Extracellular vesicles as a platform to study cell-surface membrane proteins.

A. Roussel, L. Gauthier, B. Amigues, 2020, Methods.

Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-bet–Dependent Tc1 Program with Repressed IL-6/TGF-β1 Signaling

S. Spicuglia, Julien Maurizio, A. Griffon, 2013, The Journal of Immunology.

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

L. Leserman, M. Buferne, N. Auphan-Anezin, 2012, Cancer research.